Anaspec has introduced two recombinant proteins for use in neurodegenerative disease research: a-synuclein (SNCA) and B-synuclein (SNCB).
Both a-synuclein and B-synuclein are expressed and purified from E.coli.
A-synuclein is a 140-amino acid, long recombinant protein (Genbank Accession NP000336) and B-synuclein is 134-amino-acid-long (Genbank Accession NP003076).
A-synuclein (SNCA) and B-synuclein, along with y-synuclein (SNCG), are members of the synuclein family of small proteins expressed primarily in neural tissue and in some tumours.
Synuclein proteins, found only in vertebrates, possess a highly conserved N-terminal domain, with a variable number of 11-residue repeats and a less conserved C-terminal, with a preponderance of acidic residues.
A-synuclein is used in Parkinson's disease (PD) research and B-synuclein has been shown to induce mild experimental auto-immune encephalomyelitis (EAE) in Lewis rates.
These proteins can be used in applications such as Elisa, western blots and microscopy imaging.
